Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/81682
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Rehabilitation Sciences | en_US |
dc.creator | Vanicek, T | en_US |
dc.creator | Kranz, GS | en_US |
dc.creator | Vyssoki, B | en_US |
dc.creator | Komorowski, A | en_US |
dc.creator | Fugger, G | en_US |
dc.creator | Hoflich, A | en_US |
dc.creator | Micskei, Z | en_US |
dc.creator | Milovic, S | en_US |
dc.creator | Lanzenberger, R | en_US |
dc.creator | Eckert, A | en_US |
dc.creator | Kasper, S | en_US |
dc.creator | Frey, R | en_US |
dc.date.accessioned | 2020-02-10T12:28:37Z | - |
dc.date.available | 2020-02-10T12:28:37Z | - |
dc.identifier.issn | 0001-690X | en_US |
dc.identifier.uri | http://hdl.handle.net/10397/81682 | - |
dc.language.iso | en | en_US |
dc.publisher | Wiley-Blackwell | en_US |
dc.rights | ©2019 The Authors. Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd | en_US |
dc.rights | All rights reserved | en_US |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | en_US |
dc.rights | The following publication Vanicek, T., Kranz, G. S., Vyssoki, B., Komorowski, A., Fugger, G., Hoflich, A., . . . Frey, R. (2019). Repetitive enhancement of serum BDNF subsequent to continuation ECT. Acta Psychiatrica Scandinavica, 140(5), 426-434 is available at https://dx.doi.org/10.1111/acps.13080 | en_US |
dc.subject | Depression | en_US |
dc.subject | Unipolar and bipolar affective disorder | en_US |
dc.subject | Continuation electroconvulsive therapy | en_US |
dc.subject | Brain-derived neurotrophic factor | en_US |
dc.title | Repetitive enhancement of serum BDNF subsequent to continuation ECT | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.spage | 426 | en_US |
dc.identifier.epage | 434 | en_US |
dc.identifier.volume | 140 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.doi | 10.1111/acps.13080 | en_US |
dcterms.abstract | Introduction: Continuation electroconvulsive therapy (c-ECT) is highly effective for the prevention of depressive symptom relapse. There is a lack of understanding, about how c-ECT works in humans, particularly with regard to its effects on brain derived neurotrophic factor (BDNF) concentrations. Here, we aimed to close a gap in the literature by evaluating BDNF levels in patients receiving c-ECT. | en_US |
dcterms.abstract | Methods: We included 13 patients with either unipolar or bipolar depression (mean age +/- SD: 55.5 +/- 17.1; f/m: 10/3; unipolar/bipolar: 10/3) who received between one and four c-ECT (average per patient: 2.8). Serum BDNF (sBDNF) levels were assessed before and after each c-ECT sessions. Clinical assessments were also administered both before and after treatment. | en_US |
dcterms.abstract | Results: Our analysis revealed a significant increase in sBDNF after each treatment (c-ECT 1-3: P < 0.001, c-ECT 4: P = 0.018). The application of multiple c-ECT treatments was not, however, associated with further sBDNF enhancements. Psychometric scores were not significantly altered following c-ECT. | en_US |
dcterms.abstract | Discussion: An increase in sBDNF concentrations subsequent to c-ECT parallel data from the animal literature, which has linked regularly applied electrical stimulation to neuroplastic processes. This finding suggests a relationship between ECT-induced sBDNF concentrations and (sustained) remission status, considering a stable clinical condition across c-ECT. | en_US |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Acta psychiatrica Scandinavica, Nov. 2019, v. 140, no. 5, p. 426-434 | en_US |
dcterms.isPartOf | Acta psychiatrica Scandinavica | en_US |
dcterms.issued | 2019-11 | - |
dc.identifier.isi | WOS:000486279700001 | - |
dc.identifier.scopus | 2-s2.0-85073791232 | - |
dc.identifier.eissn | 1600-0447 | en_US |
dc.description.validate | 202002 bcrc | en_US |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | a0723-n08, OA_Scopus/WOS | en_US |
dc.description.fundingSource | Others | en_US |
dc.description.fundingText | Austrian National Bank (P23021) | en_US |
dc.description.pubStatus | Published | en_US |
dc.description.oaCategory | CC | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Vanicek_Serum_BDNF_Subsequent_ECT.pdf | 401.75 kB | Adobe PDF | View/Open |
Page views
137
Last Week
2
2
Last month
Citations as of Apr 13, 2025
Downloads
100
Citations as of Apr 13, 2025
SCOPUSTM
Citations
19
Citations as of May 8, 2025
WEB OF SCIENCETM
Citations
19
Citations as of May 8, 2025

Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.